血清肿瘤标志物检测在盆腔良恶性妇科肿瘤诊断与鉴别诊断中的意义

Abstract
Figure/Table
References (15)
Related Citation (7)

Download: PDF (360 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the diagnosis and differential significance of serum tumor markers in pelvic benign and malignant gynecological tumors.Methods Fifty patients with pelvic gynecologic tumor in our hospital from July 5 to December 23,2016 were selected as the research object,According to the nature of the tumor was divided into benign and malignant group(25 cases),and 50 healthy subjects were taken as control group.All patients were given serum tumor markers to detect the detection of positive and biochemical indicators.Results The positive rate of CA153,CA125 of malignant group were 52.00%,92.00%,higher than the benign group(4.00%,60.00%),the difference was statistically significant(P<0.05),The positive rate of CEA,AFP,CA199 in the two groups had,no significant difference(P>0.05);CEA,AFP of the three groups had no statistical significance(P>0.05).In the malignant groups,CA199,CA153,CA125,respectively were[(150.89±7.06),(107.57±4.24),(446.19±10.07)U/ml],benign tumor group [(44.31±3.82),(17.15±1.38),(52.43±5.65)U/ml],were higher than[12.19±0.93),(8.02±0.46),(15.02±2.18)U/ml] of the control group,was statistically significant(P<0.05).Conclusion The detection of serum tumor markers in the diagnosis of pelvic benign and malignant gynecological tumors has a high clinical value and is favorable to the development of treatment regimens.

Key words： Pelvic benign and malignant gynecological tumors Diagnosis Serum tumor markers detection

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Jie-ru

Cite this article:

WU Jie-ru. Significance of serum tumor markers in the diagnosis and differential diagnosis of pelvic benign and malignant gynecological tumors[J]. 中国当代医药, 2017, 24(36): 123-125.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I36/123

[1]	张丽敏.MRI和血清肿瘤标志物对鉴别卵巢交界性肿瘤和Ⅰ期上皮性卵巢癌的诊断价值[D].郑州：郑州大学，2016.
[2]	黄正敏，孙丽君.卵巢癌血清肿瘤标志物的研究进展[J].中国优生优育，2013，19（9）：731-734.
[3]	彭丹红.超声放大肿瘤标志物及卵巢癌预警和早期诊断新方法的实验研究[D].南京：东南大学，2015.
[4]	肖超强，裴丽丽，何为等.常见妇科肿瘤患者血清中唾液酸化糖蛋白标志物的筛选分析[J].安徽医科大学学报，2014， 49（11）：1689-1692.
[5]	罗兵.联合检测肿瘤标志物在妇科肿瘤临床诊断中的评价及Toll样受体接头蛋白SARM、MyD88、TRIF在妇科肿瘤中表达情况的研究[D].合肥：安徽医科大学，2012.
[6]	陈冬玥.TVCDS与18F-FDG PET/CT在妇科恶性肿瘤中的应用价值比较[D].天津：天津医科大学，2014.
[7]	尹莉莉，杜叶平.CA125与妇科肿瘤的相关研究进展[J].山西医药杂志，2012，41（15）：781-782.
[8]	肖超强.常见妇科肿瘤血清中糖蛋白标志物的筛选分析[D].合肥：安徽医科大学，2014.
[9]	敬宏，牛晓宇.卵巢癌肿瘤干细胞及其标志物在卵巢癌诊疗中作用的研究进展[J].中华妇幼临床医学杂志（电子版），2017，13（2）：226-230.
[10]	赵婷婷.TCF4和E-cadherin在卵巢肿瘤中的表达及临床意义[D].合肥：安徽医科大学，2016.
[11]	王海欧.CD133、ABCG2在卵巢黏液性肿瘤中的表达及意义[D].温州：温州医科大学，2016.
[12]	曾强震.肿瘤标志物CA125和CEA在妇科肿瘤诊治中的临床价值分析[J].中国实用医药，2016，11（4）：99-100.
[13]	柴红霞，杨永秀.MACC1与妇科肿瘤的研究进展[J].中国肿瘤，2015，24（12）：1022-1025.
[14]	马丽娜.卵巢肿瘤标志物的研究进展[J].内蒙古医学杂志，2016，48（2）：183-186.
[15]	刘毅.肿瘤标志物联合检测在诊断妇科恶性肿瘤中的应用[J].包头医学院学报，2017，33（7）：28-30.